Chinese PDC pioneer broadens link-up with Wuxi
A subsidiary of WuXi AppTec (SHA: 603259) and fellow Chinese firm Coherent Biopharma have announced the signing of a strategic partnership agreement, building on a successful previously-signed collaboration.
The deal will see WuXi STA become Coherent’s preferred CDMO partner and provide it with integrated CMC services to accelerate its present and future drug candidates from API to drug product, including but not limited to the process development, manufacturing, analytical and regulatory filing support.
"I am confident that our cooperation will accelerate the pathway of our cancer drugs to market for the benefit of global patients"In recent years, peptide drug conjugates (PDCs) have attracted attention from more and more drugmakers due to advantages such as strong tumor permeation, good scalability and relatively good pharmacokinetics.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze